Karen Ho Hong
Directeur/Membre du Conseil chez BioRexis Pharmaceutical Corp.
Profil
Karen Ho Hong is currently a Director at BioRexis Pharmaceutical Corp.
and StrideBio, Inc. She is also a Partner at Novo Ventures (US), Inc. and Novo Holdings A.
In the past, she held positions as a Director at BioSyntech, Inc. and Clarus Therapeutics, Inc. She served as an Independent Director at Agile Therapeutics, Inc. from 2014 to 2016.
Karen was also a Senior Investment Director at Takeda Ventures, Inc. and an Independent Director at Cyteir Therapeutics, Inc. from 2019 to 2021.
She has experience as a Director at BiomX Ltd.
and Palleon Pharmaceuticals, Inc. Additionally, Karen worked as a Technical Consultant at BancBoston Capital, Inc. and as a Partner at ProQuest Management LLC from 2013 to 2016.
She was a Member at Ben Franklin Technology Partners.
Dr. Hong holds a doctorate degree from the Massachusetts Institute of Technology and an undergraduate degree from the University of California, Berkeley.
Postes actifs de Karen Ho Hong
| Sociétés | Poste | Début |
|---|---|---|
BioRexis Pharmaceutical Corp.
 BioRexis Pharmaceutical Corp. Pharmaceuticals: MajorHealth Technology BioRexis Pharmaceutical Corp. provides novel protein and peptide drugs with pharmacology and trans-bodies to replace conventional monoclonal antibodies. The company was founded by Christopher P. Prior, Andrew Turner and David R. King in 2002 and is headquartered in Rosemont, PA. | Directeur/Membre du Conseil | - |
Novo Ventures (US), Inc.
 Novo Ventures (US), Inc. Investment ManagersFinance Novo Ventures (US), Inc. is a venture capital firm located in San Francisco. The firm is a subsidiary of Novo A/S and their ultimate parent is Novo Nordisk Fonden. | Private Equity Investor | 01/04/2019 |
StrideBio, Inc.
 StrideBio, Inc. BiotechnologyHealth Technology Stridebio, Inc. focuses on creating and developing novel adeno-associated viral vector technologies. The company was founded by Aravind Asokan, Mavis Agbandje-McKenna and Patrick Ritschel and is headquartered in Durham, NC. | Directeur/Membre du Conseil | - |
Novo Holdings A/S (Investment Company)
 Novo Holdings A/S (Investment Company) Financial ConglomeratesFinance Novo Holdings A/S (Investment Company) (Novo Holdings-IC) is the investment portfolio division of Novo Holdings A/S, a holding company headquartered in Hellerup, Denmark. They are ultimately owned by Novo Nordisk Fonden (Novo Nordisk Foundation). Founded in 1999, Novo Holdings-IC manages a broad portfolio of the Foundation’s financial assets. | Private Equity Investor | 01/04/2019 |
Anciens postes connus de Karen Ho Hong
| Sociétés | Poste | Fin |
|---|---|---|
| CYTEIR THERAPEUTICS, INC. | Directeur/Membre du Conseil | 15/12/2021 |
| AGILE THERAPEUTICS, INC. | Directeur/Membre du Conseil | 28/07/2016 |
ProQuest Management LLC
 ProQuest Management LLC Investment ManagersFinance ProQuest Management LLC (ProQuest Management) is a venture capital firm founded in 1998 by Jay Moorin. The firm headquartered in Naples, Florida. | Private Equity Investor | 31/05/2016 |
BancBoston Capital, Inc.
 BancBoston Capital, Inc. Investment ManagersFinance Founded in 2004, BancBoston Capital, Inc. is a private equity/venture capital firm located in Boston, Massachusetts. They are a subsidiary of Bank of America NA and their ultimate parent is Bank of America Corp. (NYSE: BAC). | Corporate Officer/Principal | 31/12/2000 |
Takeda Ventures, Inc.
 Takeda Ventures, Inc. Investment ManagersFinance Takeda Ventures Inc (Takeda Ventures) is a venture capital subsidiary of Takeda America Holdings Inc founded in 2001. The firm is headquartered in Palo Alto, California. | Private Equity Investor | - |
Formation de Karen Ho Hong
| University of California, Berkeley | Undergraduate Degree |
| Massachusetts Institute of Technology | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| AGILE THERAPEUTICS, INC. | Health Technology |
| BIOSYNTECH, INC. | Health Technology |
| CYTEIR THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 11 |
|---|---|
ProQuest Management LLC
ProQuest Management LLC Investment ManagersFinance ProQuest Management LLC (ProQuest Management) is a venture capital firm founded in 1998 by Jay Moorin. The firm headquartered in Naples, Florida. | Finance |
Ben Franklin Technology Partners /Ventures/
 Ben Franklin Technology Partners /Ventures/ Investment ManagersFinance Ben Franklin Technology Partners /Ventures/ (Ben Franklin Tech Partners) is a venture Capital firm founded in 1982. The firm is headquartered in Philadelphia, Pennsylvania. | Finance |
BancBoston Capital, Inc.
BancBoston Capital, Inc. Investment ManagersFinance Founded in 2004, BancBoston Capital, Inc. is a private equity/venture capital firm located in Boston, Massachusetts. They are a subsidiary of Bank of America NA and their ultimate parent is Bank of America Corp. (NYSE: BAC). | Finance |
BioRexis Pharmaceutical Corp.
BioRexis Pharmaceutical Corp. Pharmaceuticals: MajorHealth Technology BioRexis Pharmaceutical Corp. provides novel protein and peptide drugs with pharmacology and trans-bodies to replace conventional monoclonal antibodies. The company was founded by Christopher P. Prior, Andrew Turner and David R. King in 2002 and is headquartered in Rosemont, PA. | Health Technology |
Clarus Therapeutics, Inc.
 Clarus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Clarus Therapeutics, Inc. operated as a men's health specialty pharmaceutical company that focuses on the development and commercialization of oral testosterone replacement therapy. It offered JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company was founded by Robert E. Dudley in February 2004 and was headquartered in Northbrook, IL. | Health Technology |
BiomX Ltd.
 BiomX Ltd. Pharmaceuticals: MajorHealth Technology BiomX Ltd. engages in the development of customized phage therapies designed to target and destroy harmful bacteria in chronic diseases such as inflammatory bowel disease and colorectalcancer, as well as bacteria that affect the appearance of the skin. The company was founded by Eran Elinav, Timothy K. Lu, and Rotem Sorek on March 3, 2015 and is headquartered in Ness Ziona, Israel. | Health Technology |
Palleon Pharmaceuticals, Inc.
 Palleon Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Palleon Pharmaceuticals, Inc. operates as biotechnology company. The firm discovers and develops immuno-oncology drugs, medicines, and therapies for the treatment of cancer diseases. It specializes in clinical development, and glyco-immune checkpoint inhibitors. The company was founded by Jim Broderick, Carolyn Bertozzi and Paul Crocker in 2015 and is headquartered in Waltham, MA. | Commercial Services |
Takeda Ventures, Inc.
Takeda Ventures, Inc. Investment ManagersFinance Takeda Ventures Inc (Takeda Ventures) is a venture capital subsidiary of Takeda America Holdings Inc founded in 2001. The firm is headquartered in Palo Alto, California. | Finance |
Novo Ventures (US), Inc.
Novo Ventures (US), Inc. Investment ManagersFinance Novo Ventures (US), Inc. is a venture capital firm located in San Francisco. The firm is a subsidiary of Novo A/S and their ultimate parent is Novo Nordisk Fonden. | Finance |
StrideBio, Inc.
StrideBio, Inc. BiotechnologyHealth Technology Stridebio, Inc. focuses on creating and developing novel adeno-associated viral vector technologies. The company was founded by Aravind Asokan, Mavis Agbandje-McKenna and Patrick Ritschel and is headquartered in Durham, NC. | Health Technology |
Novo Holdings A/S (Investment Company)
Novo Holdings A/S (Investment Company) Financial ConglomeratesFinance Novo Holdings A/S (Investment Company) (Novo Holdings-IC) is the investment portfolio division of Novo Holdings A/S, a holding company headquartered in Hellerup, Denmark. They are ultimately owned by Novo Nordisk Fonden (Novo Nordisk Foundation). Founded in 1999, Novo Holdings-IC manages a broad portfolio of the Foundation’s financial assets. | Finance |
